IAP-antagonists exhibit non-redundant modes of action through differential DIAP1 binding

Area of Science:

• Cell biology
• Molecular mechanisms of apoptosis
• Protein-protein interactions

Background:

• Inhibitor of apoptosis proteins (IAPs), such as DIAP1, are crucial for maintaining cell viability by inhibiting caspases.
• Apoptosis, or programmed cell death, is regulated by a balance between IAPs and IAP-antagonists.
• IAP-antagonists, including Reaper, Grim, Hid, and Jafrac2, are known to overcome IAP-mediated caspase inhibition.

Purpose of the Study:

• To provide biochemical evidence for the non-equivalent actions of IAP-antagonists.
• To elucidate the differential binding mechanisms of IAP-antagonists to DIAP1.
• To compare the caspase inhibition strategies of DIAP1 and XIAP.

Main Methods:

• Biochemical assays to assess protein binding.
• Analysis of differential binding of IAP-antagonists to specific DIAP1 BIR domains.
• Investigation of DIAP1 BIR region association with distinct caspases.

Main Results:

• IAP-antagonists Reaper, Grim, Hid, and Jafrac2 exhibit selective binding to specific DIAP1 BIR domains.
• Distinct DIAP1 BIR regions associate with different caspases, including initiator and effector caspases.
• DIAP1 lacks conserved caspase-binding residues found in XIAP; residues C-terminal to BIR1 are critical for caspase association.

Conclusions:

• The differential binding of IAP-antagonists to DIAP1 suggests they target distinct caspases for inhibition.
• DIAP1 and XIAP employ different molecular strategies to inhibit caspases.
• These findings reveal novel insights into the regulation of apoptosis by IAPs and their antagonists.